First published 10/3/2026, 1:11:15 AM · Last updated 10/3/2026, 1:11:15 AM

P2.06.86 Development and Validation of Peripheral Blood 5-Protein Signature Predicting the Efficacy of Immunotherapy in Advanced NSCLC

The source is a journal article reporting development and validation of a peripheral blood 5-protein signature that predicts immunotherapy efficacy in advanced non-small cell lung cancer (NSCLC). Additional methodological, cohort, and result details were not included in the supplied source data.

Illustrative image: Immune Blood Sample Draw — NASA/JSC/NASA Image and Video Library, NASA Media Usage Guidelines

Categories: science-and-space, public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The study reports a validated blood-based protein signature that predicts immunotherapy efficacy in advanced NSCLC.

Sources

P2.06.86 Development and Validation of Peripheral Blood 5-Protein Signature Predicting the Efficacy of Immunotherapy in Advanced NSCLC

Report an issue